文献速递肝病

停用恩替卡韦或替诺福韦的慢性乙型肝炎患者乙肝病毒复发率比较

Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
PubMed 文献 · Aliment Pharmacol Ther · 2018-11-28

本研究在342例接受恩替卡韦(ETV)和165例接受富马酸替诺福韦二吡呋酯(TDF)的无肝硬化慢性乙型肝炎(CHB)患者中比较停药后乙肝病毒(HBV)复发率。结果显示,停用TDF者的病毒学复发和临床复发率显著高于停用ETV者,且复发时间更早;倾向性评分匹配后结果一致。多因素分析显示TDF组是复发的独立因素。停药后2-3年HBsAg清除率两组相当。

要点

  • 停用TDF者病毒学复发和临床复发率显著高于停用ETV者,且复发时间更早。
  • 倾向性评分匹配的HBeAg阳性及阴性患者中,TDF组复发率仍更高。
  • 多因素分析显示TDF组是病毒学复发和临床复发的独立因素。

核心结论

  • 停用TDF后HBV复发比停用ETV后发生更早且更严重。

研究设计与样本

  • 回顾-前瞻性研究,纳入342例接受ETV(108例HBeAg阳性、234例HBeAg阴性)和165例接受TDF(46例HBeAg阳性、119例HBeAg阴性)的无肝硬化CHB患者,所有患者均符合2012年亚太肝病学会停药标准且治疗后随访至少6个月。

主要发现

  • 停用TDF者病毒学复发和临床复发率显著高于停用ETV者,且复发时间更早。
  • 在倾向性评分匹配的HBeAg阳性和HBeAg阴性患者中,同样观察到停用TDF者复发率更高且更早。
  • 多因素分析显示,TDF组是所有患者及倾向性评分匹配的HBeAg阳性和HBeAg阴性患者中病毒学复发和临床复发的独立因素。
  • 停药后随访2-3年,ETV组和TDF组HBsAg清除率相当。
  • 与ETV组相比,TDF组临床复发趋于更严重。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line long-term monotherapy for treatment of chronic hepatitis B (CHB) infection. High virological relapse rates are found after cessation of either ETV or TDF in CHB patients. AIM: To compare hepatitis B virus (HBV) relapse rates in CHB patients without cirrhosis who discontinued ETV or TDF. METHODS: A retrospective-prospective study was conducted in 342 CHB patients (108 hepatitis B e antigen (HBeAg)-positive and 234 HBeAg-negative) who received ETV and 165 (46 HBeAg-positive, 119 HBeAg-negative) who received TDF were recruited. All patients had post-treatment follow-up for at least 6 months. All fulfilled the stopping criteria of the Asia-Pacific Association for the Study of the Liver of 2012. RESULTS: Patients who discontinued TDF had significantly higher rates and earlier times of virological and clinical relapse than those who discontinued ETV. This was also seen in propensity score (PS)-matched HBeAg-positive and HBeAg-negative patients. Multivariate analysis showed that being in the TDF group was an independent factor for virological and clinical relapse in all patients and PS-matched HBeAg-positive and HBeAg-negative patients. The rate of off-therapy HBsAg loss was comparable between the ETV and TDF groups after 2-3 years follow-up. Clinical relapse tended to be more severe in the TDF group compared with the ETV group. CONCLUSION: HBV relapse occurs sooner and is more severe after cessation of TDF than after cessation of ETV.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kuo MT, Hu TH, Hung CH, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2018. PMID: 30484881. doi:10.1111/apt.15053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。